Nikhil Wagle

Title: Nikhil Wagle: Innovator in Cancer Treatment

Introduction

Nikhil Wagle is a prominent inventor based in Brookline, MA (US). He has made significant contributions to the field of cancer treatment through his innovative research and patents. With a total of 3 patents, Wagle is recognized for his work in identifying mutations that confer resistance to cancer therapies.

Latest Patents

Wagle's latest patents focus on the MEK1 mutation, which is known to confer resistance to RAF and MEK inhibitors. His patents include nucleic acids and proteins that possess a mutant MEK sequence. Additionally, he has developed methods for identifying patients who exhibit resistance to treatment with anti-cancer agents, specifically inhibitors of RAF or MEK. These methods also encompass treatment optimization for patients with mutations in the MEK1 sequence.

Career Highlights

Nikhil Wagle is affiliated with the Dana-Farber Cancer Institute Inc., where he continues to advance his research in cancer treatment. His work has been instrumental in enhancing the understanding of genetic mutations and their implications for therapy.

Collaborations

Wagle collaborates with notable colleagues, including Levi A. Garraway and Caroline Emery. Their combined expertise contributes to the ongoing research and development of innovative cancer treatments.

Conclusion

Nikhil Wagle's contributions to cancer research and treatment through his patents and collaborations highlight his role as a leading inventor in the field. His work continues to pave the way for advancements in personalized medicine and cancer therapy.